In a 26-year-old female with acute renal failure (serum creatinine 14 mg/dL), severe anemia, hyperphosphatemia, secondary hyperparathyroidism, and a positive perinuclear anti-neutrophil cytoplasmic antibody (p‑ANCA) level of 133 AU/mL after normal creatinine five months ago, what is the appropriate next management?

Immediate Induction Immunosuppression for ANCA-Associated Vasculitis with Severe Renal Involvement

This 26-year-old woman with positive p-ANCA and rapidly progressive renal failure (creatinine 14 mg/dL from normal 5 months ago) requires urgent induction therapy with rituximab or cyclophosphamide plus high-dose glucocorticoids, with strong consideration for plasma exchange given the severity of renal dysfunction. 1

Urgent Diagnostic Confirmation

While awaiting kidney biopsy results, do not delay starting immunosuppressive therapy if clinical presentation is compatible with ANCA-associated vasculitis (AAV) and serology is positive 1. The combination of:

• Positive p-ANCA (133 AU/mL)
• Rapid progression from normal creatinine to 14 mg/dL over 5 months
• Severe anemia (likely from renal failure and possible microangiopathic process)
• Hyperphosphatemia and secondary hyperparathyroidism (consistent with advanced renal failure)

...strongly suggests pauci-immune crescentic glomerulonephritis from AAV, most likely microscopic polyangiitis (MPA) given the p-ANCA/MPO pattern.

Obtain kidney biopsy urgently to confirm diagnosis and assess chronicity, but initiate treatment immediately if biopsy is delayed 1.

Induction Therapy Protocol

First-Line Immunosuppression

Choose rituximab as preferred induction agent 1:

• Rituximab 375 mg/m² weekly × 4 weeks OR 1 gram at weeks 0 and 2
• Combined with oral prednisolone 1 mg/kg/day (maximum 60-80 mg/day) for week 1, then rapid taper per protocol 1

Alternative: Cyclophosphamide if rituximab unavailable 1:

• Intravenous: 15 mg/kg at weeks 0,2,4,7,10,13 (reduced to 10 mg/kg given likely GFR <30 mL/min)
• Oral: 1.0 mg/kg/day (reduced from standard 2 mg/kg/day due to severe renal impairment)

Critical Consideration: Plasma Exchange

Strongly consider adding plasma exchange given creatinine >3.4 mg/dL 1. The 2024 KDIGO guidelines note:

• Practice Point 9.3.1.9 recommends considering plasma exchange for patients with SCr >3.4 mg/dL or requiring dialysis 1
• Evidence shows reduction in kidney failure risk at 12 months, though the PEXIVAS trial showed mixed results 1
• Given this patient's extremely elevated creatinine (14 mg/dL) and young age, the potential benefit of avoiding dialysis dependency outweighs infection risk 1, 2

Plasma exchange protocol if used: 7 exchanges over 14 days, replacing with albumin or fresh frozen plasma 2

Glucocorticoid Dosing

Start with oral prednisolone 1 mg/kg/day (approximately 60 mg for average-sized woman) 1:

• Week 1: 1 mg/kg/day
• Week 2-4: Taper to 30 mg/day
• Month 2-3: Taper to 15 mg/day
• Month 4-5: Taper to 7.5 mg/day
• Month 6: Taper to 5 mg/day, then withdraw if using rituximab 1

Consider pulse methylprednisolone 1-3 grams total if life-threatening presentation, though this lacks RCT evidence and increases toxicity 1.

Supportive Management

Immediate Renal Support

• Initiate hemodialysis given creatinine 14 mg/dL—patient likely already has uremic symptoms and volume overload
• Correct severe anemia (transfuse if hemodynamically unstable or symptomatic)
• Manage hyperphosphatemia with phosphate binders
• Address secondary hyperparathyroidism with active vitamin D analogs once phosphate controlled

Infection Prophylaxis

Mandatory Pneumocystis jirovecii prophylaxis with trimethoprim-sulfamethoxazole or atovaquone 2

Monitoring During Induction

• Weekly CBC, creatinine, urinalysis during first month
• Monitor for infections (leading cause of early mortality)
• Assess for pulmonary hemorrhage (check for hemoptysis, perform chest imaging if respiratory symptoms)

Maintenance Therapy Planning

After achieving remission (typically 3-6 months), transition to maintenance 1:

• Rituximab preferred: 500 mg every 6 months for 18-24 months (MAINRITSAN protocol) 1
• Alternative: Azathioprine 1.5-2 mg/kg/day with low-dose prednisone 5-7.5 mg/day for 2 years 1

Duration: 18 months to 4 years depending on relapse risk factors 1

Critical Pitfalls to Avoid

1. Do not wait for biopsy to start treatment in rapidly progressive disease with positive ANCA 1
2. Do not under-dose cyclophosphamide for renal impairment—reduce by 2.5 mg/kg for IV dosing when GFR <30 1
3. Do not omit PCP prophylaxis—infection is the leading cause of early death 2
4. Do not assume dialysis dependency is permanent—aggressive early treatment can restore renal function even with severe presentation 1
5. Do not use methotrexate or MMF for induction in this severe presentation—reserved for less severe disease 1

Prognosis Considerations

At creatinine 14 mg/dL, this patient has severe renal involvement with high risk of dialysis dependency. However, young age (26 years) is favorable, and aggressive treatment including plasma exchange may prevent permanent renal failure 1. The rapid progression (5 months) suggests active inflammation rather than chronic scarring, which is more amenable to treatment.

Kidney transplantation evaluation should be considered if dialysis dependency persists after achieving disease remission 2.